SCC of the prostate is associated with a more aggressive disease phenotype compared to adenocarcinoma, and is more likely to have metastasized to bone, liver or lungs at the time of diagnosis [12], to have lower prostate-specific antigen (PSA) with advanced disease [13] and has worse survival [14]. Here, KLK3 is linked to adenocarcinoma.